Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
WU-CART-007 by Wugen for T-Cell Lymphomas: Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase I...
WU-CART-007 by Wugen for T-Cell Leukemia: Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for T-Cell Leukemia. According to GlobalData, Phase I...
WU-CART-007 by Wugen for Sezary Syndrome: Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for Sezary Syndrome. According to GlobalData, Phase I...
WU-CART-007 by Wugen for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to...
WU-CART-007 by Wugen for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According to...
WU-CART-007 by Wugen for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
WU-CART-007 by Wugen for Refractory Acute Myeloid Leukemia: Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
WU-CART-007 by Wugen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
WU-CART-007 by Wugen for Lymphoblastic Lymphoma: Likelihood of Approval
WU-CART-007 is under clinical development by Wugen and currently in Phase II for Lymphoblastic Lymphoma. According to GlobalData, Phase II...